No Data
Express News | ApicHope Pharmaceutical: Injection of Yanhuoning and Shengmai Yin (Dangshen Recipe) is planned to be selected for the national Chinese Patent Medicine procurement alliance's centralized volume-based procurement.
Express News | Noon announcement: Zhejiang Wolwo Bio-Pharmaceutical has obtained registration certificates for three types of injection liquid pharmaceutical products.
Express News | ApicHope Pharmaceutical: Innovative Drug APH1727 tablets have received clinical trial approval from the USA FDA.
The flu Concept is rising, Shandong Lukang Pharmaceutical has reached its limit up, and ApicHope Pharmaceutical and others are among the top gainers.
On December 20, Gelonghui reported that the A-share influenza concept is experiencing a volatile upward trend, with Shandong Lukang Pharmaceutical hitting the limit up, and Beijing Hotgen Biotech Co., Ltd and Hybio Pharmaceutical rising over 12%. Other stocks such as Yirui Biotech, Chongqing Taiji Industry, ApicHope Pharmaceutical, and Lushang Freda Pharmaceutical also followed suit. In recent news, the China Centers for Disease Control and Prevention released a report on the recent monitoring of respiratory infectious diseases nationwide, indicating a sustained upward trend in acute respiratory infectious diseases, with a significant increase in influenza.
Express News | ApicHope Pharmaceutical: The enrollment for the pivotal global Phase III REDUCE2 trial of the Innovative Drugs AR882 has surpassed half.
ApicHope Pharmaceutical (300723.SZ): Wholly-owned subsidiary Lianrui Pharmaceutical has been recognized as a high-tech enterprise.
On December 17th, Gelonghui reported that ApicHope Pharmaceutical (300723.SZ) announced that according to the "Announcement on the Second Batch of High-tech Enterprises Filed for Recognition by Institutions in Guangdong Province for 2024" published by the National High-tech Enterprise Recognition Management Work Leading Group Office on December 17, 2024, the company's wholly-owned subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. (hereinafter referred to as "Lianrui Pharmaceutical") has been included in the second batch of high-tech enterprises filed for recognition by institutions in Guangdong Province for 2024. This is Lianrui Pharmaceutical's first time obtaining high-tech enterprise recognition, with the certificate number GR20.
